Cory Sago
Chief Executive Officer & Founder Amplitude Therapeutics
Seminars
Thursday 28th May 2026
Unlocking Trans-Amplifying RNA to Deliver Self-Amplifying Potency with Improved Manufacturability & Dosing Control • Achieve robust levels of protein expression without over
11:30 am
- Achieve robust levels of protein expression without oversized RNA constructs by separating replicase and payload RNAs to improve delivery efficiency, formulation flexibility, and translation across species
- Increased drug substance flexibility to reduce CMC, scale-up, and regulatory risk versus traditional saRNA by simplifying RNA length, improving batch consistency, and enabling more predictable manufacturing
- Expand therapeutic applicability beyond vaccines by using trans-amplifying RNA to enable tunable expression, lower dosing, and modular payload design for protein replacement and in vivo biologic delivery
Thursday 28th May 2026
Panel: Contrasting Circular vs. Self-Amplifying RNA to Match Modalities to Use-Cases
9:00 am
- Weigh strengths and trade-offs in potency, durability, manufacturability, and safety to guide platform decisions
- Compare fit-for-purpose advantages across CAR-T, protein replacement, combination therapies, autoimmune, and CNS applications to reduce risk
- Define where each modality delivers a strategic edge and where constraints limit applicability for smarter portfolio planning
Thursday 28th May 2026
Harnessing Cascade Amplification & Therapeutic Payload (CATP) Systems to Unlock Potent, Low-Dose & Multi-Payload saRNA Therapeutics
11:00 am
- Achieve strong therapeutic expression at lower doses using a two-step amplification system that combines saRNA with defective viral replication to bypass current safety– efficacy limits
- Enable multi-gene and complex therapeutic logic through a dual-amplification system capable of supporting larger and more sophisticated payloads beyond traditional vaccine applications
- Improve targeting precision and reduce off-target liver accumulation with advanced delivery design that supports tissue- and cell-type–specific uptake for safer, more predictable translation
